ARS Pharmaceuticals Net Income

The latest net income for SPRY is $-220M as of June 2026. That compares with $-48M in the prior-year period — down 348.7% year over year. That is below the Healthcare sector average of $16B. Investors often review this figure alongside ARS Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, SPRY's net income moved from $-48M to $-220M — a 348.7% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in ARS Pharmaceuticals's operating scale or balance-sheet position.

Against Healthcare companies, SPRY currently prints $-220M for net income, while the sector average sits near $16B. That is roughly 101.3% below the sector mean. Large gaps often invite a closer look at ARS Pharmaceuticals's growth, margins, and balance sheet.

A net income figure of $-220M for SPRY is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $16B. Explore the charts below for those layers of context.

After noting SPRY's net income ($-220M), review year-over-year change from $-48M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.